Optic neuritis: current challenges in diagnosis and management.
Journal
Current opinion in neurology
ISSN: 1473-6551
Titre abrégé: Curr Opin Neurol
Pays: England
ID NLM: 9319162
Informations de publication
Date de publication:
01 02 2023
01 02 2023
Historique:
entrez:
11
1
2023
pubmed:
12
1
2023
medline:
14
1
2023
Statut:
ppublish
Résumé
The primary aim of this review is to describe the clinical course, salient imaging features, and relevant serological profiles of common optic neuritis (ON) subtypes. Key diagnostic challenges and treatment options will also be discussed. ON is a broad term that describes an inflammatory optic nerve injury arising from a variety of potential causes. ON can occur sporadically, however there is particular concern for co-associated central nervous system (CNS) inflammatory syndromes including multiple sclerosis (MS), neuromyelitis optic spectrum disorders (NMOSD), and myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD). The ON subtypes that often herald MS, NMOSD, and MOGAD differ with respect to serological antibody profile and neuroimaging characteristics, yet there is significant overlap in their clinical presentations. A discerning history and thorough examination are critical to rendering the correct diagnosis. Optic neuritis subtypes vary with respect to their long-term prognosis and accordingly, require different acute treatment strategies. Moreover, delays in identifying MOGAD, and certainly NMOSD, can be highly detrimental because affected individuals are vulnerable to permanent vision loss and neurologic disability from relapses.
Identifiants
pubmed: 36630210
doi: 10.1097/WCO.0000000000001128
pii: 00019052-202302000-00003
doi:
Substances chimiques
Aquaporin 4
0
Myelin-Oligodendrocyte Glycoprotein
0
Autoantibodies
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
10-18Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992; 326:581–588.
Vanda A Lennon, Dean M Wingerchuk, Thomas Kryzer, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364:2106–2112.
Beck RW, Cleary PA, Backlund JC. The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Ophthalmology 1994; 101:1771–1778.
The Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 2008; 65:727–732.
Bennett JL, Costello F, Chen JJ, et al. Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. Lancet Neurol 2022; S1474-4422(22)00187-9.
Hassan MB, Stern C, Flanagan EP, et al. Population-based incidence of optic neuritis in the era of aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies. Am J Ophthalmol 2020; 220:110–114.
Stunkel L, Kung NH, Wilson B, et al. Incidence and causes of overdiagnosis of optic neuritis. JAMA Ophthalmol 2018; 136:76–81.
Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018; 17:162–173.
de Lott LB, Bennett JL, Costello F. The changing landscape of optic neuritis: a narrative review. J Neurol 2022; 269:111–124.
Bursztyn L, Cornblath WT. Sensitivity of magnetic resonance imaging for acute demyelinating optic neuritis. In: North American Neuro-Ophthalmology Society Meeting, San Diego, CA. 2015.
Kupersmith MJ, Alban T, Zeiffer B, Lefton D. Contrast-enhanced MRI in acute optic neuritis: relationship to visual performance. Brain 2002; 125:812–822.
McKinney AM, Lohman BD, Sarikaya B, et al. Accuracy of routine fat-suppressed FLAIR and diffusion-weighted images in detecting clinically evident acute optic neuritis. Acta Radiol 2013; 54:455–461.
Storoni M, Davagnanam I, Radon M, et al. Distinguishing optic neuritis in neuromyelitis optica spectrum disease from multiple sclerosis: a novel magnetic resonance imaging scoring system. J Neuro-Ophthalmol 2013; 33:123–127.
Traboulsee A, Simon JH, Stone L, et al. Revised recommendations of the consortium of MS centers task force for a standardized MRI protocol and clinical guidelines for the diagnosis and follow-up of multiple sclerosis. Am J Neuroradiol 2016; 37:394–401.
Optic Neuritis Study Group. The clinical profile of optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 1991; 109:1673–1678.
Volpe NJ. The Optic Neuritis Treatment Trial: a definitive answer and profound impact with unexpected results. Arch Ophthalmol 2008; 126:996–999.
Watanabe M, Nakamura Y, Michalak Z, et al. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology 2019; 93:E1299–E1311.
Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85:177–189.
Costello F. Neuromyelitis optica spectrum disorders. Continuum (Minneap Minn) 2022; 28:1131–1170.
Waters PJ, Komorowski L, Woodhall M, et al. A multicenter comparison of MOG-IgG cell-based assays. Neurology 2019; 92:E1250–E1255.
Sechi E, Buciuc M, Pittock SJ, et al. Positive predictive value of myelin oligodendrocyte glycoprotein autoantibody testing. JAMA Neurol 2021; 78:741–746.
Manzano GS, Salky R, Mateen FJ, et al. Positive predictive value of MOG-IgG for clinically defined MOG-AD within a real-world cohort. Front Neurol 2022; 13:947630.
Chen JJ, Costello F. The role of optical coherence tomography in neuro-ophthalmology. Ann Eye Sci 2018; 3:35.
Chen JJ, Sotirchos ES, Henderson AD, et al. OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and multiple sclerosis: RNFL thickening in acute optic neuritis from MOGAD vs MS. Multiple Sclerosis Related Disord 2022; 58:103525.
Lujan BJ, Horton JC. Microcysts in the inner nuclear layer from optic atrophy are caused by retrograde trans-synaptic degeneration combined with vitreous traction on the retinal surface. Brain 2013; 136:e260.
Bennett JL, de Seze J, Lana-Peixoto M, et al. Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography. Multiple Sclerosis J 2015; 21:678–688.
de Lott LB, Burke JF, Andrews CA, et al. Association of individual-level factors with visual outcomes in optic neuritis: secondary analysis of a randomized clinical trial. JAMA Network Open 2020; 3:e204339.
Morrow SA, Alexander Fraser J, Day C, et al. Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids a randomized clinical trial. JAMA Neurol 2018; 75:690–696.
Tajfirouz DA, Bhatti MT, Chen JJ. Clinical characteristics and treatment of MOG-IgG–associated optic neuritis. Curr Neurol Neurosci Rep 2019; 19:100.
Stiebel-Kalish H, Hellmann MA, Mimouni M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol NeuroInflamm 2019; 6:1–7.
Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 2019; 394:1352–1363.
Kleiter I, Gahlen A, Borisow N, et al. Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 2016; 79:206–216.
Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2018; 89:346–351.
Kumawat B, Choudhary R, Sharma C, et al. Plasma exchange as a first line therapy in acute attacks of neuromyelitis optica spectrum disorders. Ann Indian Acad Neurol 2019; 22:389–394.
Banerjee A, Ng J, Coleman J, et al. Outcomes from acute attacks of neuromyelitis optica spectrum disorder correlate with severity of attack, age and delay to treatment. Multiple Sclerosis Related Disord 2019; 28:60–63.
Whittam DH, Karthikeayan V, Gibbons E, et al. Treatment of MOG antibody associated disorders: results of an international survey. J Neurol 2020; 267:3565–3577.
Oliveira LM, Apóstolos-Pereira SL, Pitombeira MS, et al. Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis. Multiple Sclerosis J 2019; 25:1907–1914.
Chen JJ, Flanagan EP, Bhatti MT, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology 2020; 95:E111–E120.
Chen JJ, Huda S, Hacohen Y, et al. Association of maintenance intravenous immunoglobulin with prevention of relapse in adult myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol 2022; 79:518–525.
Whittam DH, Cobo-Calvo A, Lopez-Chiriboga AS, et al. Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients. Multiple Sclerosis Related Disord 2020; 44:102251.
Wingerchuk DM. Disease-modifying therapies should be stopped in NMOSD patients in remission – commentary. Multiple Sclerosis J 2019; 25:1220–1222.
Watanabe S, Misu T, Miyazawa I, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Multiple Sclerosis 2007; 13:968–974.
Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 2014; 71:324–330.
Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2020; 19:298–306.
Yang CS, Jia D, Zhang TX, et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol 2020; 19:391–401.
Torres J, Pruitt A, Balcer L, et al. Analysis of the treatment of neuromyelitis optica. J Neurol Sci 2015; 351:31–35.
Jeong IH, Park B, Kim SH, et al. Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints. Multiple Sclerosis 2016; 22:329–339.
Huang W, Wang L, Zhang B, et al. Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: a systematic review and network meta-analysis. Multiple Sclerosis Related Disord 2019; 35:246–252.
Nikoo Z, Badihian S, Shaygannejad V, et al. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol 2017; 264:2003–2009.
Levy M, Fujihara K, Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol 2021; 20:60–67.
Kim SH, Jeong IH, Hyun JW, et al. Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol 2015; 72:989–995.
Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 2019; 381:2114–2124.
Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 2020; 19:402–414.
Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 2019; 381:614–625.
Newman NJ. The optic neuritis treatment trial. Ophthalmology 2020; 127:S172–S173.
Sathiamoorthi S, Wingerchuk DM. Transient smartphone blindness: relevance to misdiagnosis in neurologic practice. Neurology 2017; 88:809–810.
Osborne B, Balcer LJ. Optic neuritis: pathophysiology, clinical features, and diagnosis. Available at: https://www.uptodate.com/contents/optic-neuritis-pathophysiology-clinical-features-anddiagnosis . 2021.
Chung H, Burton JM, Costello FE. Transient vision loss: a neuro-ophthalmic approach to localizing the diagnosis. Expert Rev Ophthalmol 2018; 13:171–185.
Ma X, Kermode AG, Hu X, Qiu W. Risk of relapse in patients with neuromyelitis optica spectrum disorder: recognition and preventive strategy. Multiple Sclerosis Related Disord 2020; 46:102522.
Rimkus CM, Schoeps VA, Boaventura M, et al. Drug-related demyelinating syndromes: understanding risk factors, pathophysiological mechanisms and magnetic resonance imaging findings. Multiple Sclerosis Related Disord 2021; 55:103146.
Cruz RA, Chaudhary S, Guevara M, Meltzer E. Neuromyelitis optica spectrum disorders (NMOSD) and connective tissue disease (CTD): an update for the rheumatologist. 2021.
Balcer LJ, Raynowska J, Nolan R, et al. Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis. Multiple Sclerosis 2017; 23:734–747.
Keltner JL, Johnson CA, Spurr JO, Beck RW. Comparison of central and peripheral visual field properties in the Optic Neuritis Treatment Trial. 1999.
Costello F. Inflammatory optic neuropathies. Continuum 2014; 20:816–837.
Chen JJ, Flanagan EP, Jitprapaikulsan J, et al. Myelin oligodendrocyte glycoprotein antibody–positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol 2018; 195:8–15.
Benard-Seguin E, Costello F. A practical approach to the diagnosis and management of optic neuritis. Ann Indian Acad Neurol 2022; 25:S48–S53.
Ishikawa H, Kezuka T, Shikishima K, et al. Epidemiologic and clinical characteristics of optic neuritis in Japan. Ophthalmology 2019; 126:1385–1398.
Jarius S, Paul F, Weinshenker BG, et al. Neuromyelitis optica. Nat Rev Disease Primers 2020; 6:85.
Majed M, Fryer JP, McKeon A, et al. Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians. Neurol Neuroimmunol NeuroInflamm 2016; 3:e231.
Jarius S, Pellkofer H, Siebert N, et al. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1. Results from 163 lumbar punctures in 100 adult patients. J Neuroinflamm 2020; 17:1.